Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP786391.RAls_MBIn_tbWJ0KdEp_R581roQSOWISBG9iGZdscUB6s130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP786391.RAls_MBIn_tbWJ0KdEp_R581roQSOWISBG9iGZdscUB6s130_assertion type Assertion NP786391.RAls_MBIn_tbWJ0KdEp_R581roQSOWISBG9iGZdscUB6s130_head.
- NP786391.RAls_MBIn_tbWJ0KdEp_R581roQSOWISBG9iGZdscUB6s130_assertion description "[Recently completed experimental animal studies, human biomarker data, vascular imaging studies, and genome-wide atherosclerosis studies provide the rationale for proceeding with clinical outcome trials directed at inhibition of secretory phospholipase A(2) and lipoprotein-associated phospholipase A(2).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP786391.RAls_MBIn_tbWJ0KdEp_R581roQSOWISBG9iGZdscUB6s130_provenance.
- NP786391.RAls_MBIn_tbWJ0KdEp_R581roQSOWISBG9iGZdscUB6s130_assertion evidence source_evidence_literature NP786391.RAls_MBIn_tbWJ0KdEp_R581roQSOWISBG9iGZdscUB6s130_provenance.
- NP786391.RAls_MBIn_tbWJ0KdEp_R581roQSOWISBG9iGZdscUB6s130_assertion SIO_000772 22802388 NP786391.RAls_MBIn_tbWJ0KdEp_R581roQSOWISBG9iGZdscUB6s130_provenance.
- NP786391.RAls_MBIn_tbWJ0KdEp_R581roQSOWISBG9iGZdscUB6s130_assertion wasDerivedFrom befree-20150227 NP786391.RAls_MBIn_tbWJ0KdEp_R581roQSOWISBG9iGZdscUB6s130_provenance.
- NP786391.RAls_MBIn_tbWJ0KdEp_R581roQSOWISBG9iGZdscUB6s130_assertion wasGeneratedBy ECO_0000203 NP786391.RAls_MBIn_tbWJ0KdEp_R581roQSOWISBG9iGZdscUB6s130_provenance.